# The Role of Endocan Expression in the Diagnosis and Grading of Precancerous Gastric Lesions

**Authors:** Mehmet Kok, Suleyman Dolu, Mehmet Emin Arayici, Gokhan Koker, Kadir Balaban, Ayhan Hilmi Cekin

PMC · DOI: 10.3390/diagnostics15111379 · 2025-05-29

## TL;DR

Endocan expression helps diagnose and grade precancerous stomach lesions, offering a potential new tool for early detection and risk assessment.

## Contribution

First study to show endocan overexpression in gastric dysplasia, suggesting its use as a diagnostic and grading biomarker.

## Key findings

- Endocan was positively expressed in 65.3% of dysplasia cases and 100% of gastric cancer cases.
- All high-grade dysplasia cases were endocan-positive, while 75.8% of low-grade cases were endocan-negative.
- Endocan expression was absent in all healthy controls.

## Abstract

Background/Aims: Gastric dysplasia is a critical precursor to gastric cancer (GC), and accurate diagnosis and grading of these lesions are essential for effective surveillance and intervention. However, current diagnostic methods such as forceps biopsy have notable limitations, underscoring the need for reliable biomarkers. This study aimed to evaluate the diagnostic and grading utility of endocan, a soluble proteoglycan secreted by activated endothelial cells, in gastric dysplastic lesions. Methods: A total of 72 patients with gastric dysplasia, 80 with gastric adenocarcinoma, and 55 healthy controls were prospectively enrolled. Endocan expression in gastric tissue samples was assessed via immunohistochemistry and semi-quantitatively graded. Statistical comparisons were made between control, dysplastic (low-grade and high-grade), and malignant groups. Results: Endocan was negatively expressed in all control subjects and positively expressed in 65.3% of the dysplasia group and 100% of the gastric cancer group (p < 0.001). Notably, all high-grade dysplasia cases were endocan-positive, whereas 75.8% of low-grade dysplasia cases were endocan-negative (p < 0.001). Conclusions: This is the first study to demonstrate that endocan is overexpressed in gastric dysplastic lesions. Tissue endocan expression may serve as a practical and robust marker for the diagnosis and grading of gastric dysplasia, potentially enhancing early detection and risk stratification in gastric carcinogenesis.

## Linked entities

- **Proteins:** ESM1 (endothelial cell specific molecule 1)
- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** ESM1 (endothelial cell specific molecule 1) [NCBI Gene 11082] {aka endocan}
- **Diseases:** GC (MESH:D013274), Gastric Lesions (MESH:D013272), dysplasia (MESH:D015792), gastric carcinogenesis (MESH:D063646)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12154503/full.md

---
Source: https://tomesphere.com/paper/PMC12154503